Top Paracetamol Brands You Should Know About

Paracetamol, known for its effective pain-relieving and fever-reducing properties, is a staple in medicine cabinets around the world. With numerous brands on the market, it can be challenging to identify which ones offer the best quality and value. Popular and reliable brands include Tylenol, Panadol, Calpol, and Feverall, each providing options for different needs and preferences. To discover more about the features, pricing, and consumer feedback of these top paracetamol brands, take a look below.

Illustration of paracetamol

Best brands of paracetamol in 2025

Tylenol

Tylenol, a brand owned by Johnson & Johnson, is one of the leading producers of paracetamol (acetaminophen), a widely used over-the-counter pain reliever. The global acetaminophen market, which includes Tylenol, was valued at approximately USD 9.8 billion in 2022 and is expected to grow at a CAGR of 4.2% to reach USD 15.2 billion by 2033. Tylenol dominates the market, particularly in North America and Europe, with the oral route of administration accounting for about 92.4% of the market share in 2022. The Asia-Pacific region, driven by countries like India and China, also significantly contributes to the demand for Tylenol and other paracetamol products. The brand's widespread availability and superior efficacy have made it a preferred choice for pain relief.

Panadol

Panadol, a prominent brand of paracetamol, is recognized for its high-quality and effective formulations, contributing significantly to the global paracetamol market. The market, expected to grow at a CAGR of 4.41% from 2024 to 2029, is driven by the widespread use of paracetamol as a safe and effective over-the-counter analgesic and antipyretic drug. Panadol, along with other brands like Tylenol, dominates the market, with North America holding the largest market share in 2024. The extended-release formulations of paracetamol, such as those offered by Panadol, enhance patient compliance and provide sustained pain relief and fever reduction, further boosting market growth. As of 2022, paracetamol was the 114th most commonly prescribed medication in the United States, highlighting its widespread use and trust in brands like Panadol.

Calpol

Calpol, a brand owned by GlaxoSmithKline, is a leading producer of paracetamol, holding around 25% of the Indian paracetamol market. In 2017-18, Calpol's annual sales in value terms fell by 2.63% to Rs 225.34 crore, despite an 11.61% increase in unit sales to 1.35 lakh units, attributed to price reductions. This brand is one of the top six paracetamol brands in India that experienced a decline in value sales but an increase in unit sales during the same period. Calpol's market presence is significant, reflecting its popularity and trust among consumers. The brand's performance is closely monitored in the context of the broader paracetamol market trends. For more information about the Calpol brand, visit their website.

Crocin

Crocin is a leading brand in the paracetamol market, known for its effective pain and fever relief products. The global Crocin market was valued at USD 4.54 billion in 2022 and is expected to grow at a CAGR of 5.14% from 2023 to 2030, reaching USD 6.79 billion by 2030. The drug segment, dominated by paracetamol, held a 71.8% revenue share in 2022, driven by its widespread use for relieving pain and fever. Crocin products, such as Crocin 120 Suspension and Crocin Pain Relief Tablets, are popular for their efficacy and gentle nature on the stomach. The brand's dominance is further supported by its presence in key markets, including North America, which holds a significant share of 40.2% in the global Crocin market. For more detailed information about their products, you can visit Crocin's official website.

Anacin

Anacin, a well-known brand in the pharmaceutical industry, is recognized for its high-quality paracetamol products. While specific data on Anacin's market share or production volumes is not readily available, the brand is part of a larger market that is expected to grow significantly, with the global paracetamol market projected to reach USD 13.72 billion by 2029, growing at a CAGR of 4.41% from 2024 to 2029. Anacin's products, often combined with other pain relievers, contribute to the overall growth driven by increased demand for effective pain relief and fever reduction medications. The approval of new formulations, such as extended-release versions, also enhances the market's expansion, offering benefits like extended medication effectiveness and improved patient compliance. However, detailed financial or production data specific to Anacin is not provided in the available sources.

Fevadol

Fevadol, a prominent brand in the paracetamol market, is recognized for its high-quality and effective formulations. The paracetamol market, which includes brands like Fevadol, is expected to reach USD 11.06 billion by 2024 and grow at a CAGR of 4.41% to 2029. Fevadol's products, like other leading brands, ensure a bioavailability of 63-89% and an onset of action within 37 minutes when taken orally. The brand's commitment to meeting USP specifications and maintaining stringent quality control parameters ensures consumer trust and safety. With the Asia Pacific region driving the market's growth, Fevadol remains a significant player in the global paracetamol market.

Doliprane

Doliprane, a paracetamol-based medication, is one of the most popular and effective pain relievers, particularly in France, where it has been a staple since its creation in 1964. It is the best-selling medicine in France, with 2.5 billion pills produced in 2022 and 454 million boxes sold, highlighting its widespread use and consumer trust. Doliprane is produced by Opella, a subsidiary of Sanofi, and its production employs 1,700 people in France. The brand's sales have been significant, with $56 million in sales in some markets, making it a leading brand in the pharmaceutical industry. Its effectiveness in treating headaches and fever has solidified its position as a top choice for consumers. For more insights, you can explore Doliprane's impact and production details.

Paralen

Paralen, a prominent brand of paracetamol, is widely recognized for its high-quality and effective pain relief and fever reduction properties. It is sold in several countries including the Czech Republic, Poland, Slovakia, Croatia, Lithuania, Bosnia & Herzegovina, Bulgaria, North Macedonia, Serbia, and Norway. The paracetamol market, which includes brands like Paralen, is expected to grow at a CAGR of 4.41% from 2024 to 2029, reaching a market size of USD 13.72 billion by 2029. Paralen's popularity is partly due to the increasing need for pain management and the rising chronic disease burden in these regions. The brand's presence in multiple European countries underscores its reliability and widespread acceptance. For more information about various paracetamol brand names, please visit the linked resource.

Tempra

Tempra, a brand synonymous with quality paracetamol products, stands out as a leading producer in the global market. The paracetamol market, expected to reach USD 11.06 billion by 2024 and grow at a CAGR of 4.41% until 2029, is dominated by key players like GlaxoSmithKline, which is associated with the Tempra brand. Tempra's products are known for their efficacy in treating fever, headaches, and migraines, with North America being a significant market due to high prevalence of these conditions. The brand's strong presence is further bolstered by the increasing patient pool and disposable income in regions like the United States. As the Asia Pacific region is expected to be the fastest-growing market, Tempra's global reach and reputation continue to expand.

Pacimol

Paracetamol, often associated with the brand name Pacimol, is a widely used analgesic and antipyretic drug produced by several major pharmaceutical companies. While Pacimol as a brand may not be specifically highlighted as a leading producer, companies like GlaxoSmithKline, Teva Pharmaceuticals, and Sanofi are key players in the paracetamol market, which is expected to reach USD 13.72 billion by 2029, growing at a CAGR of 4.41% from 2024 to 2029. The market experienced significant growth during the COVID-19 pandemic due to increased demand for over-the-counter analgesics. Asia Pacific is the fastest-growing region, whereas North America holds the largest market share. The production of paracetamol involves the acetylation of *para*-aminophenol, a process that has been refined over the years to ensure high-quality products.